Core Viewpoint - Ruizhi Pharmaceutical has successfully turned around its financial performance in the first half of 2025, achieving a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, compared to a loss of 62.91 million yuan in the same period last year, marking a significant turnaround with a growth rate of 140.35% [1][2][8] Financial Performance - The company's gross profit margin improved significantly from 16.30% to 29.01%, an increase of 12.71 percentage points, indicating enhanced operational efficiency and cost control [2][3] - In Q2 2025, the company reported a revenue of 273 million yuan, up 18.2% year-on-year, and a net profit of 18.74 million yuan, reflecting a substantial quarter-on-quarter growth of 182% [3][4] Business Segments - The large molecule business segment saw remarkable growth of 54.68%, reaching 105 million yuan, driven by increased demand in areas such as ADC (antibody-drug conjugates) and bispecific antibodies [4][6] - The pharmacokinetics and pharmacodynamics segment generated 293 million yuan, a year-on-year increase of 13.44%, with the number of clients growing to 475 [4][6] - The chemical business segment's revenue remained stable at 131 million yuan, primarily due to intense competition and a shift of some clients towards biopharmaceuticals [4][6] Strategic Initiatives - Under the leadership of WOO SWEE LIAN, the company has restructured its organization and refocused its strategic priorities, enhancing its "full-package service" model to provide more efficient drug development solutions [6][7] - The company has established several strategic partnerships, including a ten-year collaboration with Saint No Pharmaceuticals to advance small nucleic acid drug development, leveraging each other's strengths [7][8] - The company is expanding its global presence, particularly in the U.S. and Europe, by increasing its business development team and participating in industry conferences [7][8] Industry Context - The global CRO market is experiencing a growth rate of approximately 8.5%, while the Chinese CRO market, although still in double digits, has shown signs of slowing compared to previous years [1][6] - Other CRO companies have also reported positive performance, indicating a broader recovery in the industry, with WuXi AppTec achieving a revenue of 20.8 billion yuan, up 20.64% year-on-year [7][8]

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

智通财经APP讯，睿智医药(300149.SZ)发布2025年半年度报告，该公司营业收入为5.34亿元，同比增长 14.75%。归属于上市公司股东的净利润为2538.21万元。归属于上市公司股东的扣除非经常性损益的净 利润为679.23万元。基本每股收益为0.051元。 ...

智通财经APP讯，睿智医药(300149.SZ)发布2025年半年度报告，该公司营业收入为5.34亿元，同比增长 14.75%。归属于上市公司股东的净利润为2538.21万元。归属于上市公司股东的扣除非经常性损益的净 利润为679.23万元。基本每股收益为0.051元。 ...

Group 1 - The core point of the article is that Ruizhi Pharmaceutical (SZ 300149) held its sixth board meeting on August 28, 2025, to review the semi-annual report and related documents [1] - For the fiscal year 2024, the revenue composition of Ruizhi Pharmaceutical is 99.03% from pharmaceutical research and development services and production outsourcing, while other businesses account for 0.97% [1] - As of the report, the market capitalization of Ruizhi Pharmaceutical is 6.2 billion yuan [1]

格隆汇8月28日丨睿智医药(300149.SZ)公布2025年半年度报告，上半年公司实现营业收入5.34亿元，同 比增长14.75%；归属于上市公司股东的净利润2538.21万元；归属于上市公司股东的扣除非经常性损益 的净利润679.23万元；基本每股收益0.0510元。 ...

睿智医药科技股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | 限公司 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 广东弘元普康医疗科技有限 | | 其他应收款 | 206.08 | 2.40 | | | 208.48 | 统借统还、往来 | 非经营性往来 | | | 公司 | | | | | | | | 款 | | | | 成都睿智化学研究有限公司 | | 其他应收款 | 0 | 22.67 | | 10.41 | 12.26 | 应收服务费 | 经营性往来 | | 小计 | | | | 44,490.77 | 3,031.07 | 490.98 | 1,122.62 | 46,890.20 | | 经营性往来 | | | ShangPharma Innovation, Inc. | | 应收账款 | 66.13 | 51.09 | | 0.00 | 117.22 | 应收服务费 | | | | 江苏怀瑜药业有限公司 | | 应收账款 | ...

1、审议通过了《关于2025年半年度报告全文及摘要的议案》 公司2025年半年度报告真实反映了公司的经营情况。具体内容详见公司同 日在巨潮资讯网（www.cninfo.com.cn）披露的《2025年半年度报告》及《2025 年半年度报告摘要》。 本议案已经公司董事会审计委员会审议通过。 证券代码：300149 证券简称：睿智医药 公告编号：2025-58 睿智医药科技股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第十次会议 于 2025 年 8 月 28 日以现场结合通讯方式召开。会议通知以书面、电话或电子 邮件方式送达。会议应到董事 6 人，实到 6 人。会议由公司董事长WOO SWEE LIAN先生主持，公司高级管理人员列席了会议。本次会议召集与召开 符合有关法律、行政法规、部门规章和《公司章程》的有关规定。经与会董事 认真审议，形成决议如下： 本议案以6票同意，0票反对，0票弃权获得通过。 特此公告。 睿智医药科技股份有限公司 董事会 2025 年8月28 ...

睿智医药公告，2025年上半年净利润为2538.21万元，同比扭亏为盈。 ...

睿智医药科技股份有限公司 2025 年半年度报告全文 2025 年 08 月 睿智医药科技股份有限公司 2025 年半年度报告 1 睿智医药科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责 任。 公司负责人 WOO SWEE LIAN、主管会计工作负责人查胤群及会计机构 负责人（会计主管人员）查胤群声明：保证本半年度报告中财务报告的真实、 准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司存在服务需求下降的风险、核心技术及管理人员流失的风险、新技术 开发失败的风险、营运资金不足限制规模扩张的风险、环保及安全生产的风险、 境外业务风险、突发事件和不可抗力事件影响的风险等，敬请广大投资者注意 投资风险。公司在本报告第三节"管理层讨论与分析"中的"公司面临 ...